ARWR vs GRAL
ARWR: A clinical-stage biotechnology company pioneering RNA interference (RNAi) therapeutics to treat a wide array of genetic and chronic diseases by silencing disease-causing genes. GRAL: GRAIL is developing Galleri, a blood-based multi-cancer early detection test designed to detect many types of cancer from a single draw and pinpoint the tissue of origin, pending FDA approval.
Side-by-side fundamentals
| Metric | ARWR | GRAL | Edge |
|---|---|---|---|
| Price as of 2026-07-22 close | $88.70 | $70.66 | |
| Market cap as of 2026-07-23 | $13.0B | $3.0B | |
| PEG as of 2026-07-23 | -0.62 | n/a | |
| Net margin as of 2026-07-23 | -48.4% | -253.2% | ARWR higher |
| Gross margin as of 2026-07-23 | +100.0% | +49.3% | ARWR higher |
| Operating margin as of 2026-07-23 | -35.7% | -348.7% | ARWR higher |
| ROE as of 2026-07-23 | -55.5% | -16.4% | GRAL higher |
| ROA as of 2026-07-23 | -18.1% | -14.3% | GRAL higher |
| Debt / equity as of 2026-07-23 | 2.06 | 0.00 | GRAL lower |
| Revenue growth (YoY) as of 2026-07-23 | +14.1% | +19.4% | GRAL higher |
| Revenue CAGR (3y) SEC XBRL | +50.5% | +25.7% | ARWR higher |
| Beta as of 2026-07-23 | 1.29 | 2.25 | |
| 1-year return as of 2026-07-22 close | +406.6% | +111.7% | ARWR higher |
Fundamentals: Finnhub, as of 2026-07-23. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-22.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.